{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:03:47Z","timestamp":1794330227343,"version":"4.9.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81873604"],"award-info":[{"award-number":["81873604"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chongqing medical scientific research project","award":["2022GDRC005"],"award-info":[{"award-number":["2022GDRC005"]}]},{"DOI":"10.13039\/501100005230","name":"Chongqing Natural Science Foundation","doi-asserted-by":"crossref","award":["CSTB2022NSCQ-MSX0984"],"award-info":[{"award-number":["CSTB2022NSCQ-MSX0984"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CQMU Program for Youth lnnovation in Future Medicine","award":["W0173"],"award-info":[{"award-number":["W0173"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04441-1","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T05:55:42Z","timestamp":1745906142000},"page":"3287-3298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic progress in the targeting of B cells in lupus nephritis: pathogenesis to clinical research"],"prefix":"10.1007","volume":"57","author":[{"given":"Beibei","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"issue":"3","key":"4441_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2022-223035","volume":"82","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yao X, Huang Y, Lu Q (2023) Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis 82(3):351\u2013356. https:\/\/doi.org\/10.1136\/ard-2022-223035","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4441_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","volume":"76","author":"SV Parikh","year":"2020","unstructured":"Parikh SV, Almaani S, Brodsky S, Rovin BH (2020) Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis 76(2):265\u2013281. https:\/\/doi.org\/10.1053\/j.ajkd.2019.10.017","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"4441_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41584-023-00925-5","volume":"19","author":"CC Mok","year":"2023","unstructured":"Mok CC, Teng YKO, Saxena R, Tanaka Y (2023) Treatment of lupus nephritis: consensus, evidence and perspectives. Nat Rev Rheumatol 19(4):227\u2013238. https:\/\/doi.org\/10.1038\/s41584-023-00925-5","journal-title":"Nat Rev Rheumatol"},{"key":"4441_CR4","doi-asserted-by":"publisher","first-page":"102871","DOI":"10.1016\/j.jaut.2022.102871","volume":"132","author":"C Yu","year":"2022","unstructured":"Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X (2022) Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun 132:102871. https:\/\/doi.org\/10.1016\/j.jaut.2022.102871","journal-title":"J Autoimmun"},{"issue":"11","key":"4441_CR5","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2215\/CJN.11340922","volume":"17","author":"B Wooden","year":"2022","unstructured":"Wooden B, Radhakrishnan J (2022) The role of anti-B cell activating factor therapy for treating lupus nephritis. Clin J Am Soc Nephrol 17(11):1583\u20131585. https:\/\/doi.org\/10.2215\/CJN.11340922","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"4441_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/BOR.0000000000000777","volume":"33","author":"A Chang","year":"2021","unstructured":"Chang A, Clark MR, Ko K (2021) Cellular aspects of the pathogenesis of lupus nephritis. Curr Opin Rheumatol 33(2):197\u2013204. https:\/\/doi.org\/10.1097\/BOR.0000000000000777","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"4441_CR7","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1084\/jem.180.4.1295","volume":"180","author":"MJ Shlomchik","year":"1994","unstructured":"Shlomchik MJ, Madaio MP, Ni D, Trounstein M, Huszar D (1994) The role of B cells in lpr\/lpr-induced autoimmunity. J Exp Med 180(4):1295\u20131306. https:\/\/doi.org\/10.1084\/jem.180.4.1295","journal-title":"J Exp Med"},{"issue":"8","key":"4441_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1681\/ASN.V281345","volume":"2","author":"D Vlahakos","year":"1992","unstructured":"Vlahakos D, Foster MH, Ucci AA, Barrett KJ, Datta SK, Madaio MP (1992) Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. J Am Soc Nephrol 2(8):1345\u20131354. https:\/\/doi.org\/10.1681\/ASN.V281345","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4441_CR9","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.4049\/jimmunol.172.6.3913","volume":"172","author":"H Sekine","year":"2004","unstructured":"Sekine H, Watanabe H, Gilkeson GS (2004) Enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL\/MpJ-Fas(lpr) mice. J Immunol 172(6):3913\u20133921. https:\/\/doi.org\/10.4049\/jimmunol.172.6.3913","journal-title":"J Immunol"},{"key":"4441_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.24","author":"DJ Rawlings","year":"2017","unstructured":"Rawlings DJ et al (2017) Altered B cell signalling in autoimmunity. Nat Rev Immunol. https:\/\/doi.org\/10.1038\/nri.2017.24","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4441_CR11","doi-asserted-by":"publisher","first-page":"e20211004","DOI":"10.1084\/jem.20211004","volume":"219","author":"Y He","year":"2022","unstructured":"He Y, Gallman AE, Xie C et al (2022) P2RY8 variants in lupus patients uncover a role for the receptor in immunological tolerance. J Exp Med 219(1):e20211004. https:\/\/doi.org\/10.1084\/jem.20211004","journal-title":"J Exp Med"},{"key":"4441_CR12","doi-asserted-by":"publisher","first-page":"102861","DOI":"10.1016\/j.jaut.2022.102861","volume":"132","author":"H Lou","year":"2022","unstructured":"Lou H, Ling GS, Cao X (2022) Autoantibodies in systemic lupus erythematosus: from immunopathology to therapeutic target. J Autoimmun 132:102861. https:\/\/doi.org\/10.1016\/j.jaut.2022.102861","journal-title":"J Autoimmun"},{"issue":"2","key":"4441_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1681\/ASN.2010050515","volume":"22","author":"M Espeli","year":"2011","unstructured":"Espeli M, B\u00f6kers S, Giannico G et al (2011) Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol 22(2):296\u2013305. https:\/\/doi.org\/10.1681\/ASN.2010050515","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4441_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12929-018-0436-2","volume":"25","author":"SK Devarapu","year":"2018","unstructured":"Devarapu SK, Anders HJ (2018) Toll-like receptors in lupus nephritis. J Biomed Sci 25(1):35. https:\/\/doi.org\/10.1186\/s12929-018-0436-2. (Published 2018 Apr 12)","journal-title":"J Biomed Sci"},{"issue":"45","key":"4441_CR15","doi-asserted-by":"publisher","first-page":"E6195","DOI":"10.1073\/pnas.1507052112","volume":"112","author":"T Celhar","year":"2015","unstructured":"Celhar T, Hopkins R, Thornhill SI et al (2015) RNA sensing by conventional dendritic cells is central to the development of lupus nephritis. Proc Natl Acad Sci U S A 112(45):E6195\u2013E6204. https:\/\/doi.org\/10.1073\/pnas.1507052112","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"4441_CR16","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1080\/15548627.2015.1052206","volume":"11","author":"CG Weindel","year":"2015","unstructured":"Weindel CG, Richey LJ, Bolland S, Mehta AJ, Kearney JF, Huber BT (2015) B cell autophagy mediates TLR7-dependent autoimmunity and inflammation. Autophagy 11(7):1010\u20131024. https:\/\/doi.org\/10.1080\/15548627.2015.1052206","journal-title":"Autophagy"},{"issue":"10","key":"4441_CR17","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.4049\/jimmunol.1400098.","volume":"192","author":"SW Jackson","year":"2014","unstructured":"Jackson SW, Scharping NE, Kolhatkar NS et al (2014) Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation. J Immunol 192(10):4525\u20134532. https:\/\/doi.org\/10.4049\/jimmunol.1400098.","journal-title":"J Immunol"},{"issue":"9","key":"4441_CR18","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1681\/ASN.2013010026","volume":"24","author":"M Lech","year":"2013","unstructured":"Lech M, Anders HJ (2013) The pathogenesis of lupus nephritis. J Am Soc Nephrol 24(9):1357\u20131366. https:\/\/doi.org\/10.1681\/ASN.2013010026","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"4441_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jim.2010.06.009","volume":"363","author":"T D\u00f6rner","year":"2011","unstructured":"D\u00f6rner T, Jacobi AM, Lee J, Lipsky PE (2011) Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods 363(2):187\u2013197. https:\/\/doi.org\/10.1016\/j.jim.2010.06.009","journal-title":"J Immunol Methods"},{"key":"4441_CR20","doi-asserted-by":"publisher","first-page":"852162","DOI":"10.3389\/fmed.2022.852162","volume":"9","author":"I Parodis","year":"2022","unstructured":"Parodis I, Gomez A, Lindblom J, Chow JW, Doria A, Gatto M (2022) Early changes in B and plasma cell subsets and traditional serological markers as predictors of SRI-4 response to therapy in systemic lupus erythematosus. Front Med (Lausanne). 9:852162. https:\/\/doi.org\/10.3389\/fmed.2022.852162. (Published 2022 Apr 28)","journal-title":"Front Med (Lausanne)."},{"issue":"22","key":"4441_CR21","doi-asserted-by":"publisher","first-page":"13941","DOI":"10.3390\/ijms232213941","volume":"23","author":"I Parodis","year":"2022","unstructured":"Parodis I, Gomez A, Lindblom J et al (2022) B cell kinetics upon therapy commencement for active extrarenal systemic lupus erythematosus in relation to development of renal flares: results from three phase III clinical trials of belimumab. Int J Mol Sci 23(22):13941. https:\/\/doi.org\/10.3390\/ijms232213941. (Published 2022 Nov 11)","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4441_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.immuni.2007.01.009","volume":"26","author":"T Tiller","year":"2007","unstructured":"Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H (2007) Autoreactivity in human IgG+ memory B cells. Immunity 26(2):205\u2013213. https:\/\/doi.org\/10.1016\/j.immuni.2007.01.009","journal-title":"Immunity"},{"issue":"10","key":"4441_CR23","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","volume":"165","author":"M Odendahl","year":"2000","unstructured":"Odendahl M, Jacobi A, Hansen A et al (2000) Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 165(10):5970\u20135979. https:\/\/doi.org\/10.4049\/jimmunol.165.10.5970","journal-title":"J Immunol"},{"issue":"2","key":"4441_CR24","doi-asserted-by":"publisher","first-page":"102736","DOI":"10.1016\/j.autrev.2020.102736","volume":"20","author":"T M\u00f6ckel","year":"2021","unstructured":"M\u00f6ckel T, Basta F, Weinmann-Menke J, Schwarting A (2021) B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev 20(2):102736. https:\/\/doi.org\/10.1016\/j.autrev.2020.102736","journal-title":"Autoimmun Rev"},{"issue":"5","key":"4441_CR25","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s10875-013-9887-0","volume":"33","author":"SK Chauhan","year":"2013","unstructured":"Chauhan SK, Singh VV, Rai R, Rai M, Rai G (2013) Distinct autoantibody profiles in systemic lupus erythematosus patients are selectively associated with TLR7 and TLR9 upregulation. J Clin Immunol 33(5):954\u2013964. https:\/\/doi.org\/10.1007\/s10875-013-9887-0","journal-title":"J Clin Immunol"},{"issue":"3","key":"4441_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1191\/096120398678919949","volume":"7","author":"R Herrera-Esparza","year":"1998","unstructured":"Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R, Avalos-D\u00edaz E (1998) Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus 7(3):154\u2013158. https:\/\/doi.org\/10.1191\/096120398678919949","journal-title":"Lupus"},{"issue":"6","key":"4441_CR27","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.4049\/jimmunol.178.6.3822","volume":"178","author":"D Herber","year":"2007","unstructured":"Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K (2007) IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 178(6):3822\u20133830. https:\/\/doi.org\/10.4049\/jimmunol.178.6.3822","journal-title":"J Immunol"},{"issue":"2","key":"4441_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","volume":"24","author":"AR Rezvani","year":"2011","unstructured":"Rezvani AR, Maloney DG (2011) Rituximab resistance. Best Pract Res Clin Haematol 24(2):203\u2013216. https:\/\/doi.org\/10.1016\/j.beha.2011.02.009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"4441_CR29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222\u2013233. https:\/\/doi.org\/10.1002\/art.27233","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4441_CR30","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64(4):1215\u20131226. https:\/\/doi.org\/10.1002\/art.34359","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4441_CR31","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","volume":"72","author":"MB Condon","year":"2013","unstructured":"Condon MB, Ashby D, Pepper RJ et al (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72(8):1280\u20131286. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202844","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4441_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5152\/eurjrheum.2018.17096","volume":"5","author":"F Alshaiki","year":"2018","unstructured":"Alshaiki F, Obaid E, Almuallim A, Taha R, El-Haddad H, Almoallim H (2018) Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol 5(2):118\u2013126. https:\/\/doi.org\/10.5152\/eurjrheum.2018.17096","journal-title":"Eur J Rheumatol"},{"issue":"4S","key":"4441_CR33","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group KDIGO 2021","year":"2021","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group KDIGO 2021 (2021) Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 100(4S):S1\u2013S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"issue":"1","key":"4441_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/1744666X.2023.2145281","volume":"19","author":"E Krustev","year":"2023","unstructured":"Krustev E, Clarke AE, Barber MRW (2023) B cell depletion and inhibition in systemic lupus erythematosus. Expert Rev Clin Immunol 19(1):55\u201370. https:\/\/doi.org\/10.1080\/1744666X.2023.2145281","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"4441_CR35","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.38037","volume":"65","author":"EF Mysler","year":"2013","unstructured":"Mysler EF, Spindler AJ, Guzman R et al (2013) Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65(9):2368\u20132379. https:\/\/doi.org\/10.1002\/art.38037","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4441_CR36","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00393-020-00788-1","volume":"79","author":"BF Hoyer","year":"2020","unstructured":"Hoyer BF (2020) \u201cNeue Therapien beim systemischen Lupus erythematodes\u201d [New treatments for systemic lupus erythematosus]. Z Rheumatol 79(4):342\u2013350. https:\/\/doi.org\/10.1007\/s00393-020-00788-1","journal-title":"Z Rheumatol"},{"issue":"1","key":"4441_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD et al (2022) B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81(1):100\u2013107. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220920","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4441_CR38","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/art.39026","volume":"67","author":"M Dall\u2019Era","year":"2015","unstructured":"Dall\u2019Era M, Cisternas MG, Smilek DE et al (2015) Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthr Rheumatol 67(5):1305\u20131313. https:\/\/doi.org\/10.1002\/art.39026","journal-title":"Arthr Rheumatol"},{"key":"4441_CR39","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fmed.2020.00316","volume":"7","author":"I Parodis","year":"2020","unstructured":"Parodis I, Stockfelt M, Sj\u00f6wall C (2020) B cell therapy in systemic lupus erythematosus: from rationale to clinical practice. Front Med (Lausanne). 7:316. https:\/\/doi.org\/10.3389\/fmed.2020.00316. (Published 2020 Jul 9)","journal-title":"Front Med (Lausanne)."},{"issue":"11","key":"4441_CR40","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1136\/annrheumdis-2017-211191","volume":"76","author":"MY Md Yusof","year":"2017","unstructured":"Md Yusof MY, Shaw D, El-Sherbiny YM et al (2017) Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis 76(11):1829\u20131836. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211191","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4441_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","volume":"73","author":"DJ Wallace","year":"2014","unstructured":"Wallace DJ, Kalunian K, Petri MA et al (2014) Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73(1):183\u2013190. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202760","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4441_CR42","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/art.39856","volume":"69","author":"ME Clowse","year":"2017","unstructured":"Clowse ME, Wallace DJ, Furie RA et al (2017) Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind placebo-controlled trials. Arthr Rheumatol 69(2):362\u2013375. https:\/\/doi.org\/10.1002\/art.39856","journal-title":"Arthr Rheumatol"},{"issue":"8","key":"4441_CR43","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","volume":"29","author":"D Roccatello","year":"2023","unstructured":"Roccatello D, Fenoglio R, Caniggia I et al (2023) Daratumumab monotherapy for refractory lupus nephritis. Nat Med 29(8):2041\u20132047. https:\/\/doi.org\/10.1038\/s41591-023-02479-1","journal-title":"Nat Med"},{"issue":"12","key":"4441_CR44","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/art.42652","volume":"75","author":"JT Merrill","year":"2023","unstructured":"Merrill JT, Guthridge J, Smith M et al (2023) Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial. Arthritis Rheumatol 75(12):2185\u20132194. https:\/\/doi.org\/10.1002\/art.42652","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"4441_CR45","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","volume":"18","author":"X Jin","year":"2021","unstructured":"Jin X, Xu Q, Pu C et al (2021) Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol 18(8):1896\u20131903. https:\/\/doi.org\/10.1038\/s41423-020-0472-1","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"4441_CR46","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1038\/s41591-022-02091-9","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D et al (2023) Author correction: anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 29(11):2956. https:\/\/doi.org\/10.1038\/s41591-022-02091-9","journal-title":"Nat Med"},{"issue":"9767","key":"4441_CR47","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721\u2013731. https:\/\/doi.org\/10.1016\/S0140-6736(10)61354-2","journal-title":"Lancet"},{"issue":"12","key":"4441_CR48","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthr Rheum 63(12):3918\u20133930. https:\/\/doi.org\/10.1002\/art.30613","journal-title":"Arthr Rheum"},{"issue":"1","key":"4441_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/0961203312465781","volume":"22","author":"MA Dooley","year":"2013","unstructured":"Dooley MA, Houssiau F, Aranow C et al (2013) Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22(1):63\u201372. https:\/\/doi.org\/10.1177\/0961203312465781","journal-title":"Lupus"},{"issue":"11","key":"4441_CR50","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2215\/CJN.02520322","volume":"17","author":"R Furie","year":"2022","unstructured":"Furie R, Rovin BH, Houssiau F et al (2022) Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study. Clin J Am Soc Nephrol 17(11):1620\u20131630. https:\/\/doi.org\/10.2215\/CJN.02520322","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"4441_CR51","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","volume":"101","author":"BH Rovin","year":"2022","unstructured":"Rovin BH, Furie R, Teng YKO et al (2022) A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int 101(2):403\u2013413. https:\/\/doi.org\/10.1016\/j.kint.2021.08.027","journal-title":"Kidney Int"},{"issue":"12","key":"4441_CR52","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383(12):1117\u20131128. https:\/\/doi.org\/10.1056\/NEJMoa2001180","journal-title":"N Engl J Med"},{"issue":"6","key":"4441_CR53","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y (2021) Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 43(6):666\u2013673. https:\/\/doi.org\/10.1080\/08923973.2021.1973493","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"4441_CR54","doi-asserted-by":"publisher","first-page":"1169084","DOI":"10.3389\/fimmu.2023.1169084","volume":"14","author":"J Cai","year":"2023","unstructured":"Cai J, Gao D, Liu D, Liu Z (2023) Telitacicept for autoimmune nephropathy. Front Immunol 14:1169084. https:\/\/doi.org\/10.3389\/fimmu.2023.1169084. (Published 2023 Jun 5)","journal-title":"Front Immunol"},{"issue":"4","key":"4441_CR55","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D et al (2024) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 83(4):475\u2013487. https:\/\/doi.org\/10.1136\/ard-2023-224854. (Published 2024 Mar 12)","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4441_CR56","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.12669\/pjms.39.4.7542","volume":"39","author":"S Liu","year":"2023","unstructured":"Liu S, Yu X, Li X (2023) A new promising biological agent for refractory lupus nephritis: Telitacicept. Pak J Med Sci. 39(4):1217\u20131218. https:\/\/doi.org\/10.12669\/pjms.39.4.7542","journal-title":"Pak J Med Sci."},{"issue":"2","key":"4441_CR57","doi-asserted-by":"publisher","first-page":"e001074","DOI":"10.1136\/lupus-2023-001074","volume":"10","author":"HZ Jin","year":"2023","unstructured":"Jin HZ, Li YJ, Wang X et al (2023) Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study. Lupus Sci Med. 10(2):e001074. https:\/\/doi.org\/10.1136\/lupus-2023-001074. (Published 2023 Nov 24)","journal-title":"Lupus Sci Med."},{"issue":"9","key":"4441_CR58","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s10157-024-02501-x","volume":"28","author":"X Huang","year":"2024","unstructured":"Huang X, Lin F, Chen H (2024) Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study. Clin Exp Nephrol 28(9):902\u2013909. https:\/\/doi.org\/10.1007\/s10157-024-02501-x","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"4441_CR59","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/1756285610371146","volume":"3","author":"HP Hartung","year":"2010","unstructured":"Hartung HP, Kieseier BC (2010) Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord 3(4):205\u2013216. https:\/\/doi.org\/10.1177\/1756285610371146","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"4441_CR60","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","volume":"74","author":"D Isenberg","year":"2015","unstructured":"Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D (2015) Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 74(11):2006\u20132015. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205067. (published correction appears in Ann Rheum Dis. 2016 May;75(5):946. 10.1136\/annrheumdis-2013-205067corr1)","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"4441_CR61","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1177\/0961203316650734","volume":"25","author":"BH Rovin","year":"2016","unstructured":"Rovin BH, Dooley MA, Radhakrishnan J, Ginzler EM, Forrester TD, Anderson PW (2016) The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials. Lupus 25(14):1597\u20131601. https:\/\/doi.org\/10.1177\/0961203316650734","journal-title":"Lupus"},{"issue":"9","key":"4441_CR62","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","volume":"74","author":"RA Furie","year":"2015","unstructured":"Furie RA, Leon G, Thomas M et al (2015) A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis 74(9):1667\u20131675. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205144","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4441_CR63","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","volume":"77","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS (2018) Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 77(6):883\u2013889. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213032","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4441_CR64","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/art.42462","volume":"75","author":"LS Evans","year":"2023","unstructured":"Evans LS, Lewis KE, DeMonte D et al (2023) Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases. Arthritis Rheumatol 75(7):1187\u20131202. https:\/\/doi.org\/10.1002\/art.42462","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"4441_CR65","doi-asserted-by":"publisher","first-page":"e70055","DOI":"10.1111\/cts.70055","volume":"17","author":"R Davies","year":"2024","unstructured":"Davies R, Peng SL, Lickliter J et al (2024) A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF\/APRIL antagonist, in healthy adults. Clin Transl Sci 17(11):e70055. https:\/\/doi.org\/10.1111\/cts.70055","journal-title":"Clin Transl Sci"},{"issue":"10","key":"4441_CR66","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/art.38074","volume":"65","author":"LM Carter","year":"2013","unstructured":"Carter LM, Isenberg DA, Ehrenstein MR (2013) Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthr Rheum 65(10):2672\u20132679. https:\/\/doi.org\/10.1002\/art.38074","journal-title":"Arthr Rheum"},{"issue":"1","key":"4441_CR67","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.41466","volume":"73","author":"Y Atisha-Fregoso","year":"2021","unstructured":"Atisha-Fregoso Y, Malkiel S, Harris KM et al (2021) Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthr Rheumatol. 73(1):121\u2013131. https:\/\/doi.org\/10.1002\/art.41466. (published correction appears in Arthritis Rheumatol. 2021 Dec;73(12):2356)","journal-title":"Arthr Rheumatol."},{"key":"4441_CR68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","volume":"91","author":"T Kraaij","year":"2018","unstructured":"Kraaij T, Kamerling SWA, de Rooij ENM et al (2018) The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun 91:45\u201354. https:\/\/doi.org\/10.1016\/j.jaut.2018.03.003","journal-title":"J Autoimmun"},{"key":"4441_CR69","doi-asserted-by":"publisher","first-page":"952304","DOI":"10.3389\/fmed.2022.952304","volume":"9","author":"I Parodis","year":"2022","unstructured":"Parodis I, Gatto M, Sj\u00f6wall C (2022) B cells in systemic lupus erythematosus: targets of new therapies and surveillance tools. Front Med (Lausanne). 9:952304. https:\/\/doi.org\/10.3389\/fmed.2022.952304. (Published 2022 Aug 30)","journal-title":"Front Med (Lausanne)."},{"issue":"12","key":"4441_CR70","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.7326\/M21-2078","volume":"174","author":"M Shipa","year":"2021","unstructured":"Shipa M, Embleton-Thirsk A, Parvaz M et al (2021) Effectiveness of belimumab after rituximab in systemic lupus erythematosus\u202f: a randomized controlled trial. Ann Intern Med 174(12):1647\u20131657. https:\/\/doi.org\/10.7326\/M21-2078","journal-title":"Ann Intern Med"},{"issue":"10381","key":"4441_CR71","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand EF, Vital EM, Petri M et al (2023) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 401(10381):1001\u20131010. https:\/\/doi.org\/10.1016\/S0140-6736(22)02607-1","journal-title":"Lancet"},{"issue":"10381","key":"4441_CR72","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri M, Bruce IN, D\u00f6rner T et al (2023) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 401(10381):1011\u20131019. https:\/\/doi.org\/10.1016\/S0140-6736(22)02546-6","journal-title":"Lancet"},{"key":"4441_CR73","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/annrheumdis-2023-eular.53","volume":"82","author":"M Hassanien","year":"2023","unstructured":"Hassanien M, Moshrif A, Hetta H (2023) Efficacy and safety of baricitinib in patients with active lupus nephritis: a double-blind, randomized, placebo-controlled phase 3 trial. Ann Rheum Dis 82:34\u201335. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.53","journal-title":"Ann Rheum Dis"},{"key":"4441_CR74","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.3389\/fimmu.2017.01986","volume":"8","author":"AB Satterthwaite","year":"2018","unstructured":"Satterthwaite AB (2018) Bruton\u2019s tyrosine kinase, a component of b cell signaling pathways, has multiple roles in the pathogenesis of lupus. Front Immunol 8:1986. https:\/\/doi.org\/10.3389\/fimmu.2017.01986. (Published 2018 Jan 22)","journal-title":"Front Immunol"},{"key":"4441_CR75","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.clim.2018.10.008","volume":"197","author":"SA Chalmers","year":"2018","unstructured":"Chalmers SA, Glynn E, Garcia SJ et al (2018) BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. Clin Immunol 197:205\u2013218. https:\/\/doi.org\/10.1016\/j.clim.2018.10.008","journal-title":"Clin Immunol"},{"issue":"1","key":"4441_CR76","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/acr2.11511","volume":"5","author":"DJ Wallace","year":"2023","unstructured":"Wallace DJ, D\u00f6rner T, Pisetsky DS et al (2023) Efficacy and safety of the bruton\u2019s tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind Placebo-Controlled Dose-Ranging Trial. ACR Open Rheumatol 5(1):38\u201348. https:\/\/doi.org\/10.1002\/acr2.11511","journal-title":"ACR Open Rheumatol"},{"key":"4441_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914526","author":"Y Renaudineau","year":"2023","unstructured":"Renaudineau Y et al (2023) Lupus nephritis risk factors and biomarkers: an update. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241914526","journal-title":"Int J Mol Sci"},{"key":"4441_CR78","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2138340","author":"DYH Yap","year":"2022","unstructured":"Yap DYH, Mok CC (2022) Novel and emerging treatment strategies for lupus nephritis. Expert Rev Clin Pharmacol. https:\/\/doi.org\/10.1080\/17512433.2022.2138340","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04441-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04441-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04441-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:00:04Z","timestamp":1758808804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04441-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":78,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["4441"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04441-1","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This review article does not involve human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All the authors provided consent for the publication of this manuscript and confirmed its accuracy and originality.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}